B Cell News and Research

RSS

GICD, Stanford University collaborate to develop stem cell and regenerative medicine therapies

Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) and Stanford University School of Medicine will collaborate in a new consortium funded by the National Heart, Lung and Blood Institute (NHLBI) to develop stem cell and regenerative medicine therapies. GICD investigators, led by GICD Director Deepak Srivastava, MD, will collaborate with a Stanford team led by Robert Robbins, MD, professor and chair of cardiothoracic surgery, to investigate how to use induced pluripotent stem cells, or iPS cells, to repair damaged heart muscle.

3 Nov 2009

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor.

3 Nov 2009

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.

3 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

AllOne Health(SM) and Connectyx Technologies Holdings Group, Inc. (Pink Sheets: CTYX) today announced a partnership that will allow consumers to view and manage health information on the Web, via portable USB storage devices and through their mobile phones, with one, secure step. A package including both companies' products will be sold in retail stores across the U.S. in December.

2 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced that it has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population.

2 Nov 2009

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA).

2 Nov 2009

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months.

2 Nov 2009

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer.

2 Nov 2009

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies.

2 Nov 2009

Saft expands its portfolio with VL 10V Fe Super-Phosphate technology

Saft, the world specialist in the design and manufacture of high-tech batteries for industry, has expanded its range of lithium technologies with the VL 10V Fe Super-Phosphate(TM), the highest power lithium iron phosphate cell on the market. These large cells are designed for defense applications, such as U.S. Navy undersea operations, requiring very high power and safe operation.

2 Nov 2009

Local businesses team up to address youth homelessness

STANDUP FOR KIDS has been chosen by STAR OF THE NEIGHBORHOOD's "Featured Charity" program where thousands of local businesses are being asked to join forces for charity www.starkart.net/charity.

2 Nov 2009

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

WCMC-Q's biomedical research program makes significant progress

The biomedical research program of Weill Cornell Medical College in Qatar has made significant progress in its dual goals of advancing basic science and building a sustainable research community in Qatar since it was launched less than a year and a half ago.

2 Nov 2009

Combination of inhibitor and antioxidants may help prevent diabetes complications

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

Stress-evoked changes in circuits that regulate serotonin in certain parts of the brain can precipitate a low mood and a relapse in cocaine-seeking, based on mouse studies published online this week in the Proceedings of the National Academy of Sciences.

31 Oct 2009

Johns Hopkins researchers find life in blood-starved retinas; shed light on vision loss

Like all tissues in the body, the eye needs a healthy blood supply to function properly. Poorly developed blood vessels can lead to visual impairment or even blindness. While many of the molecules involved in guiding the development of the intricate blood vessel architecture are known, only now are we learning how these molecules work and how they might affect sight.

31 Oct 2009

B Cell News and Research

GICD, Stanford University collaborate to develop stem cell and regenerative medicine therapies

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

NIH awards $2 million grant for sickle cell disease research

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

VEGF from the retinal pigment epithelium to the choriocapillaris leads to degeneration of the CC, study finds

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Saft expands its portfolio with VL 10V Fe Super-Phosphate technology

Local businesses team up to address youth homelessness

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

WCMC-Q's biomedical research program makes significant progress

Combination of inhibitor and antioxidants may help prevent diabetes complications

Amgen publishes Phase 3 study results of Aranesp

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

Johns Hopkins researchers find life in blood-starved retinas; shed light on vision loss

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News